Discuss with your doctor or care team
Print this page with details about the trial or email it to your doctor to discuss the clinical trial during your next visit.
Trial purpose
The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria as assessed by blinded independent central review (BICR).
 |
NATIONAL TRIAL REFERENCE NUMBER | NCT05947851 |
 |
Conditions | CLL, Leukemia, Chronic Lymphocytic, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic, SLL, Small-Cell Lymphoma |
 |
Age Range | 18+ |
 |
Sex | All |
|
Current trial phase | 1 |
|
Trial start and end dates | [08-08-2023] [06-27-2033] |
About the trial
Eligibility
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Conditions
CLL, Leukemia, Chronic Lymphocytic, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic, SLL, Small-Cell Lymphoma
Phase 3
In Phase 3 trials, researchers try to find out if a treatment works in a large number of people, usually about 1,000 to 5,000 participants who have the health condition the treatment is intended to treat. In vaccine trials, the participants may be healthy or have diseases or conditions. Phase 3 trials may happen in a doctor’s office, a clinic, or a hospital.
Trial locations (3)
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.